Defrance T, Carayon P, Billian G, Guillemot J C, Minty A, Caput D, Ferrara P
Unité d'Immunologie et Stratégie Vaccinale, Institut Pasteur de Lyon, France.
J Exp Med. 1994 Jan 1;179(1):135-43. doi: 10.1084/jem.179.1.135.
The recently cloned human interleukin 13 (IL-13) is a novel cytokine expressed in activated T cells that has been shown to inhibit inflammatory cytokine production by lipopolysaccharide-activated monocytes. The protein encoded by the IL-13 cDNA is the human homologue of a mouse Th2-product called P600. Here, we show that IL-13 acts at different stages of the B cell maturation pathway: (a) it enhances the expression of CD23/Fc epsilon RII and class II MHC antigens on resting B cells; (b) it stimulates B cell proliferation in combination with anti-Ig and anti-CD40 antibodies; and (c) it induces IgE synthesis. Thus, the spectrum of the biological activities of IL-13 on B cells largely overlaps that previously ascribed to IL-4. The present observations suggest that IL-13 may be an important factor, in addition to IL-4, in the development of allergic diseases.
最近克隆出的人白细胞介素13(IL-13)是一种在活化T细胞中表达的新型细胞因子,已证明它能抑制脂多糖激活的单核细胞产生炎性细胞因子。IL-13 cDNA编码的蛋白质是一种名为P600的小鼠Th2产物的人类同源物。在此,我们表明IL-13作用于B细胞成熟途径的不同阶段:(a)它增强静息B细胞上CD23/FcεRII和II类MHC抗原的表达;(b)它与抗Ig和抗CD40抗体联合刺激B细胞增殖;(c)它诱导IgE合成。因此,IL-13对B细胞的生物活性谱在很大程度上与先前归因于IL-4的谱重叠。目前的观察结果表明,除IL-4外,IL-13可能是过敏性疾病发展中的一个重要因素。